Atherosclerotic cardiovascular disease screening and management
protocols among adult HIV clinics in Asia

DC Boettiger1,2*, MG Law3, J Ross3, BV Huynh3, BSL Heng3, R Ditangco6, S Kiertiburanakul1, A Avihingsanon6, DD Cuong9, N Kumarasamy10, A Kamarulzaman11, PS Ly12, E Yunihasut13, T Parwati Merati14, F Zhang15, S Khusuwan16, R Chaiwiarith17, MP Lee18, S Sangles19, JY Choi20, WW Ku21, J Tanuma22, DT Ng23, AH Sohn24, CW Wester25, D Nash26,28, C Mugglin27 and S Pujari28 on behalf of the International Epidemiology Databases to Evaluate AIDS – Asia-Pacific

Abstract

Objectives: Integration of HIV and non-communicable disease services improves the quality and efficiency of care in low- and middle-income countries (LMICs). We aimed to describe current practices for the screening and management of atherosclerotic cardiovascular disease (ASCVD) among adult HIV clinics in Asia.

Methods: Sixteen LMIC sites included in the International Epidemiology Databases to Evaluate AIDS – Asia-Pacific network were surveyed.

Results: Sites were mostly (81%) based in urban public referral hospitals. Half had protocols to assess tobacco and alcohol use. Protocols for assessing physical inactivity and obesity were in place in 31% and 38% of sites, respectively. Most sites provided educational material on ASCVD risk factors (between 56% and 75% depending on risk factors). A total of 94% reported performing routine screening for hypertension, 100% for hyperlipidaemia and 88% for diabetes. Routine ASCVD risk assessment was reported by 94% of sites. Protocols for the management of hypertension, hyperlipidaemia, diabetes, high ASCVD risk and chronic ischaemic stroke were in place at 50%, 69%, 56%, 19% and 38% of sites, respectively. Blood pressure monitoring was free for patients at 69% of sites; however, most required patients to pay some or all of the costs for other ASCVD-related procedures. Medications available in the clinic or within the same facility were included angiotensin-converting enzyme inhibitors (81%), statins (94%) and sulphonylureas (94%).

Conclusion: The consistent availability of clinical screening, diagnostic testing and procedures and the availability of ASCVD medications in the Asian LMIC clinics surveyed are strengths that should be leveraged to improve the implementation of cardiovascular care protocols.

Keywords: HIV, cardiovascular disease, atherosclerosis, hypertension, Asia

Introduction

While AIDS-related infections, malignancies and deaths have declined among people living with HIV (PLHIV) in the antiretroviral therapy (ART) era, there has been a concomitant increase in non-AIDS-related causes of death [1–3]. This trend is consistent with the dramatic global increase in population rates of non-communicable disease over the past three decades [4]; however, many studies now show that PLHIV experience a disproportionate amount of this burden [5–7]. Although partly due to the high prevalence of traditional risk factors among PLHIV, the increase in non-AIDS-related causes of death may also be associated with the persistent low-level inflammation induced by long-term ART and HIV infection itself [8].

Atherosclerotic cardiovascular disease (ASCVD) is now a leading cause of non-AIDS-related death among people on ART [9–11]. However, in many low- and middle-income countries (LMICs), ASCVD is managed episodically, thereby placing patients at risk of long-term complications [12]. In contrast, HIV programmes

*Corresponding author: David C Boettiger
Institute for Health Policy Studies, University of California, San Francisco, 3333 California Street, 94118, USA
Email: dboettiger@kirby.unsw.edu.au
in LMICs have proven very successful in establishing long-term care models that focus on continuity of care and retention, routine monitoring, and reduction in HIV transmission risk. Integration of HIV and non-communicable disease services has been shown to improve the quality and efficiency of care among PLHIV in LMICs [13,14], and was recommended by the World Health Organization in their action plan for the prevention and control of non-communicable diseases in Southeast Asia from 2013 to 2020 [15]. UNAIDS estimates that 5.9 million people are currently living with HIV in Asia [16]. Nevertheless, data remain limited with regard to the infrastructure and human resources available for non-communicable disease care among HIV clinics in the region.

Here we describe current practices for ASCVD screening and management among HIV clinics in LMICs in Asia. Our data will inform current and future research in the region and help policymakers develop more effective strategies to prevent and manage ASCVD among PLHIV.

Methods

The International Epidemiology Databases to Evaluate AIDS (IeDEA; www.iedea.org) is a global consortium that includes cohorts located in Asia-Pacific, Caribbean, South and North America, and Central, East, Southern and West Africa [17–20]. IeDEA provides a unique platform for evaluating standard practices and resource allocation in HIV cohorts in these regions. In 2016, a survey of LMIC (as defined by World Bank [21]) sites in IeDEA was conducted to assess site capacity for non-communicable disease screening and management [22–24]. A follow-up survey was conducted in 2018 across sites in the IeDEA Asia-Pacific network to further evaluate screening and management practices for ASCVD. We have assessed the results from both surveys.

Investigators from IeDEA developed and standardised a 302-question survey on site resources, lifestyle assessment and education practices, screening and management of non-communicable diseases (hypertension, diabetes, kidney and pulmonary disease, mental health disorders and cancer), care for paediatric and adolescent patients, availability of vaccinations, imaging, surgery and medicines and routine data collection procedures. The IeDEA Site Capacity Survey is available from the authors on request. Multilingual versions of the survey were implemented using Research Electronic Data Capture (REDCap), a secure, web-based application designed to support data capture for research studies (www.project-redcap.org). REDCap was developed at the Vanderbilt Institute for Clinical and Translational Research. It provides an interface for validated data entry, audit trails for tracking data manipulation, and automated import and export procedures to common statistical packages [25]. Separate REDCap databases were created for each of the participating regions and could be completed directly online or transferred from paper copies. Regional data centres coordinated distribution to and completion of the survey by the sites. Clinical site investigators affiliated with the IeDEA regional networks were primarily responsible for completing the surveys. Data collection for IeDEA Asia-Pacific was completed by October 2016.

Investigators from IeDEA Asia-Pacific developed an additional 66-question survey to supplement the above mentioned site capacity survey. The survey containing the additional questions is available from the authors on request. Questions related to hyperlipidaemia screening and management, ASCVD risk assessment and management, chronic ischaemic stroke management, and access to lipid lowering and anti-diabetic medicines. Although ASCVD risk assessment tools are limited in their capacity to predict stroke risk accurately [26], we did not enquire about whether sites used additional means to assess stroke risk to prevent the survey becoming overly burdensome. An English version of the survey was implemented using REDCap, which allowed data to be entered directly online. Sites could also complete the survey on paper and send scanned files to the IeDEA Asia-Pacific coordinating centre (TREAT Asia/amfAR, Bangkok, Thailand) for data entry. Clinical site investigators and data managers affiliated with IeDEA Asia-Pacific were primarily responsible for completing the surveys. Data collection was completed by June 2018. An additional question on beta-blocker availability was put to the sites via email in October 2019.

Analysis

All 16 LMIC sites in IeDEA Asia-Pacific participated in the global site capacity and regional ASCVD surveys. Countries included were Thailand (four sites), China (two sites), India (two sites), Indonesia (two sites), Malaysia (two sites), Vietnam (two sites), Cambodia (one site) and the Philippines (one site). Data from both surveys were combined and responses evaluated for inconsistencies, which were resolved through direct communication with site data managers. The results were split into eight categories: (1) general site characteristics; (2) risk factor assessment and patient education practices; (3) hypertension screening and management; (4) hyperlipidaemia screening and management; (5) diabetes screening and management; (6) ASCVD risk assessment and management, and chronic ischaemic stroke management; (7) availability of clinical testing and procedure; and (8) availability of medicines.

Results

General site characteristics

Sites were mostly (81%) based in urban public referral hospitals. Seventy-five percent were linked to an academic medical centre. The median number of active outpatients was 2649 (interquartile range 1500–7500) and total number of active outpatients across all sites was 81,426. Cardiology services were within the HIV clinic itself or available in the same facility for 75% of sites.

Risk factor assessment and patient education practices

Approximately half of sites had protocols to assess tobacco (50%), alcohol (50%) and other substance use (56%), as well as family history of chronic illnesses (50%). Protocols for assessing physical inactivity and obesity were in place at 31% and 38% of sites, respectively. Most sites provided educational material to patients on tobacco (75%), alcohol (69%) and other substance use (56%), physical inactivity (63%), and obesity and nutrition (69%). The most common means of education was patient counselling (Table 1).

Hypertension screening and management

Ninety-four percent of sites reported performing routine screening for hypertension, with 64% indicating that they had a protocol in place (Table 2). Most sites (88%) did not have any selection criteria for performing hypertension screening and most (81%) conducted screening at every visit. Fifty percent of sites had a protocol in place for hypertension management.

Hyperlipidaemia screening and management

All sites reported performing routine screening for hyperlipidaemia, with 44% having a protocol in place. Available screening tests included total cholesterol (75% of sites), high-density lipoprotein cholesterol (63% of sites), low-density lipoprotein cholesterol
Atherosclerotic cardiovascular disease screening and management protocols among adult HIV clinics in Asia

(69% of sites) and triglycerides (75% of sites). A protocol for hyperlipidaemia management was in place at 69% of sites. Further details on hyperlipidaemia screening and management procedures are shown in Table 3.

Diabetes screening and management

Eighty-eight percent of sites reported performing routine screening for diabetes, with 56% indicating that they had a protocol in place (Table 4). The most frequent method used for diabetes screening was a fasting plasma glucose measurement (81% of sites). Fifty percent of sites had a protocol in place for diabetes management.

Atherosclerotic cardiovascular disease risk assessment and management, and chronic ischaemic stroke management

Routine assessment of ASCVD risk was reported by 94% of sites, of which 25% reported having a protocol of any kind in place and 6%, a protocol specifically for PLHIV (Table 5). The most commonly used risk equations were Framingham (56%) and the American College of Cardiology and American Heart Association pooled cohort (50%; respondents could select more than one option). Nineteen percent of sites reported assessing ASCVD risk among all patients and 63%, only among high-risk groups. A protocol for managing patients at high risk of ASCVD was in place at 19% of sites, and 6% of sites had an HIV-specific protocol. Thirty-eight percent of sites reported having a protocol for chronic ischaemic stroke management; however, no site had a protocol specifically for PLHIV.

Clinical testing and procedure availability

Blood pressure monitoring was available in all but one (94%) of the sites surveyed. Other tests and procedures were usually available either within the HIV clinic itself or in the same facility as the HIV clinic: glycosylated haemoglobin (HbA1c, 81%), fasting

---

### Table 1. Assessment and patient education for individual risk factors (N=16)

| Characteristic                        | Tobacco use n (%) | Alcohol use n (%) | Other substance use n (%) | Physical inactivity n (%) | Obesity and nutrition n (%) | Family history of chronic illness |
|--------------------------------------|------------------|------------------|---------------------------|--------------------------|----------------------------|----------------------------------|
| Written protocol in place to assess  | 8 (50)           | 8 (50)           | 9 (56)                    | 5 (31)                   | 6 (38)                     | 8 (50%)                          |
| Educational material provided to patients | 12 (75)         | 11 (69)          | 9 (56)                    | 10 (63)                  | 11 (69)                    | NA                               |
| Primary patient education method used | Counselling      | 5 (31)           | 5 (31)                    | 3 (19)                   | 5 (31)                     | 5 (31)                           |
|                                      | Group education  | 1 (6)            | 1 (6)                     | 1 (6)                    | 1 (6)                      | 2 (13)                           |
|                                      | Referral         | 1 (6)            | 1 (6)                     | 1 (6)                    | 0 (0)                      | 2 (13)                           |
|                                      | Written information | 3 (19)        | 2 (13)                    | 3 (19)                   | 1 (6)                      | 1 (6)                            |
|                                      | Unspecified      | 2 (13)           | 2 (13)                    | 1 (6)                    | 3 (19)                     | 1 (6)                            |

*Respondents could select more than one option.

### Table 2. Hypertension screening and management (N=16)

| Characteristic                        | n (%) | Characteristic                        | n (%) |
|--------------------------------------|-------|--------------------------------------|-------|
| Routine screening for hypertension   | 15 (94)| Protocol for hypertension management | 251–500 |
| Protocol for hypertension in place   | 9 (56) | >500                                 | 8 (50) |
| Screening tests used*                |       | Protocol for hypertension management | 2 (13) |
| Manual blood pressure measurement    | 9 (56) | Location of hypertension management |       |
| Automated blood pressure measurement | 8 (50) | Within HIV clinic                     | 11 (69) |
| Ambulatory 24-hour blood pressure monitoring | 2 (13) | In same facility but not in HIV clinic | 3 (19) |
| Patients assessed for hypertension   |       | Off site                             | 2 (13) |
| All                                  | 14 (88) | Undefined                             | 0 (0) |
| High-risk groups                     | 0 (0)  | Not available                         | 0 (0) |
| Other selection                      | 0 (0)  | Staff primarily responsible for hypertension management | 10 (63) |
| Undefined                            | 2 (13) | HIV physician                        | 10 (63) |
| Timing of hypertension screening*    |       | Non-HIV physician                    | 0 (0)  |
| At enrolment into care              | 5 (31) | Nurse                                | 0 (0)  |
| At antiretroviral therapy initiation | 4 (25) | Nurse assistant                       | 1 (6)  |
| Yearly                               | 1 (6)  | Other clinical staff                 | 0 (0)  |
| At every visit                       | 13 (81)| Non-clinical staff                   | 0 (0)  |
| Number of patients screened for hypertension per month |       | Uncertain                            | 5 (31) |
| 0–100                                | 1 (6)  | Training received in past 2 years for staff managing hypertension | 10 (63) |
| 101–250                              | 3 (19) |                                       |       |
### Table 3. Hyperlipidaemia screening and management (N=16)

| Characteristic                                                                 | n (%) | Characteristic                                                                 | n (%) |
|--------------------------------------------------------------------------------|-------|--------------------------------------------------------------------------------|-------|
| Routine screening for hyperlipidaemia                                          | 16 (100) | Nurse                                                                           | 0 (0) |
| Protocol for hyperlipidaemia screening                                         | 7 (44)  | Nurse assistant                                                                  | 0 (0) |
| Screening tests used<sup>a</sup>                                               |        | Other clinical staff                                                             | 1 (6)  |
| Fasting blood lipids                                                            | 15 (94) | Non-clinical staff                                                               | 0 (0)  |
| Non-fasting blood lipids                                                        | 1 (6)  | Uncertain                                                                        | 0 (0)  |
| Total cholesterol                                                                | 12 (75) | Payment of hyperlipidaemia screening costs                                      |       |
| High-density lipoprotein (HDL) cholesterol                                      | 10 (63) | Patient only                                                                     | 5 (31) |
| Low-density lipoprotein (LDL) cholesterol                                       | 11 (69) | Full public funding                                                              | 6 (38) |
| Triglycerides                                                                   | 12 (75) | Co-payment (patient and public)                                                  | 4 (25) |
| Patients assessed for hyperlipidaemia                                          |        | Protocol for hyperlipidaemia management                                          | 11 (69) |
| All                                                                             | 11 (69) | Location of hyperlipidaemia management                                          |       |
| High-risk groups                                                                | 2 (13)  | Within HIV clinic                                                                | 14 (88) |
| Other selection                                                                 | 3 (19)  | In same facility but not in HIV clinic                                          | 1 (6)  |
| Undefined                                                                       | 0 (0)  | Off site                                                                         | 0 (0)  |
| Timing of hyperlipidaemia screening<sup>a</sup>                                 |        | Undefined                                                                        | 0 (0)  |
| At enrolment into care                                                          | 3 (19)  | Not available                                                                     | 1 (6)  |
| At antiretroviral therapy initiation                                            | 3 (19)  | Staff primarily responsible for hyperlipidaemia management                       |       |
| Yearly                                                                          | 13 (81) | HIV physician                                                                     | 13 (81) |
| At every visit                                                                  | 1 (6)  | Non-HIV physician                                                                | 0 (0)  |
| Number of patients screened for hyperlipidaemia per month                       |        | Nurse                                                                            | 0 (0)  |
| 0–100                                                                           | 3 (19)  | Nurse assistant                                                                   | 0 (0)  |
| 101–250                                                                         | 4 (25)  | Other clinical staff                                                             | 1 (6)  |
| 251–500                                                                         | 4 (25)  | Non-clinical staff                                                                | 2 (13) |
| >500                                                                            | 3 (19)  | Uncertain                                                                        | 0 (0)  |
| Uncertain                                                                       | 2 (13)  | Training received in past 2 years for staff managing hyperlipidaemia             | 10 (63) |
| Location of hyperlipidaemia screening                                          |        | Payment of hyperlipidaemia management costs                                     |       |
| Within HIV clinic                                                               | 13 (81) | Patient only                                                                     | 5 (31) |
| In same facility but not in HIV clinic                                         | 2 (13)  | Full public funding                                                              | 6 (38) |
| Off site                                                                        | 0 (0)  | Co-payment (patient and public)                                                  | 1 (6)  |
| Undefined                                                                       | 1 (6)  | Mixture of all                                                                   |       |
| Not available                                                                    | 0 (0)  |                                                                                  |       |
| Staff primarily responsible for hyperlipidaemia screening                       |        |                                                                                  |       |
| HIV physician                                                                    | 15 (94) |                                                                                  |       |
| Non-HIV physician                                                                | 0 (0)  |                                                                                  |       |

<sup>a</sup>Respondents could select more than one option.

### Table 4. Diabetes screening and management (N=16)

| Characteristic                                           | n (%) | Characteristic                                           | n (%) |
|----------------------------------------------------------|-------|----------------------------------------------------------|-------|
| Routine screening for diabetes                           | 14 (88%) | Timing of diabetes screening<sup>a</sup>                  |       |
| Protocol for diabetes screening in place                 | 9 (56%)  | At enrolment into care                                   | 5 (31%) |
| Screening tests used<sup>a</sup>                         |       | At antiretroviral therapy initiation                      | 5 (31%) |
| Random plasma glucose measurement                        | 7 (44%)  | Yearly                                                   | 4 (25%) |
| Fasting plasma glucose measurement                       | 13 (81%) | At every visit                                           | 3 (19%) |
| 2-hour plasma glucose tolerance test                     | 4 (25%)  | Number of patients screened for diabetes per month       |       |
| HbA1c                                                    | 6 (38%)  | 0–100                                                    | 6 (38%) |
| Patients assessed for diabetes                          |        | 101–250                                                  | 5 (31%) |
| All                                                      | 9 (56%)  | 251–500                                                  | 1 (6%)  |
| High-risk groups                                         | 2 (13%)  | >500                                                     | 3 (19%) |
| Other selection                                          | 0 (0%)   | Uncertain                                                | 1 (6%)  |
| Undefined                                                | 3 (19%)  |                                                          |       |

<sup>a</sup>Respondents could select more than one option.
### Table 4. Diabetes screening and management (N=16) (continued)

| Characteristic                                      | n (%) | Characteristic                                      | n (%) |
|-----------------------------------------------------|-------|-----------------------------------------------------|-------|
| Protocol for diabetes management                    | 8 (50%) | Non-HIV physician                                   | 0 (0%) |
| Location of diabetes management                     |       | Nurse                                              | 0 (0%) |
| Within HIV clinic                                    | 9 (56%) | Nurse assistant                                     | 0 (0%) |
| In same facility but not in HIV clinic               | 4 (25%) | Other clinical staff                                | 0 (0%) |
| Off site                                             | 1 (6%)  | Non-clinical staff                                  | 0 (0%) |
| Undefined                                           | 1 (6%)  | Uncertain                                          | 7 (44%) |
| Not available                                       | 1 (6%)  | Training received in past 2 years for staff managing| 10 (63) |
| Staff primarily responsible for diabetes management  |       | diabetes                                             |       |
| HIV physician                                       | 9 (56%) |                                                   |       |

*a Respondents could select more than one option. Hba1c: glycosylated haemoglobin.

### Table 5. ASCVD risk assessment and management, and chronic ischaemic stroke management (N=16)

| Characteristic                                      | n (%) | Characteristic                                      | n (%) |
|-----------------------------------------------------|-------|-----------------------------------------------------|-------|
| Routine assessment of ASCVD risk                    | 15 (94) | Nurse                                              | 1 (6)  |
| Protocol for ASCVD risk assessment                  | 4 (25)  | Nurse assistant                                     | 0 (0)  |
| HIV–specific protocol                                | 1 (6)   | Other clinical staff                                | 0 (0)  |
| Cardiovascular disease risk calculators used*       |       | Non-clinical staff                                  | 1 (6)  |
| Data collection on adverse events of anti-HIV drugs  | 2 (13)  | Uncertain                                          | 1 (6)  |
| (D:A:D)                                             |       | Protocol for managing those with high risk of ASCVD | 3 (19) |
| Framingham                                          | 9 (56)  | HIV-specific protocol                               | 1 (6)  |
| American College of Cardiology                      | 8 (50)  | Protocol for chronic ischaemic stroke management    | 6 (38) |
| Other                                               | 0 (0)   | HIV-specific protocol                               | 0 (0)  |
| Patients assessed for ASCVD risk                    |       | Location of chronic ischaemic stroke management     |       |
| All                                                 | 3 (19)  | Within HIV clinic                                   | 4 (25) |
| High-risk groups                                    | 10 (63) | In same facility but not in HIV clinic              | 9 (56) |
| Other selection                                     | 2 (13)  | Off site                                            | 2 (13) |
| None                                                | 1 (6)   | Undefined                                           | 0 (0)  |
| Timing of ASCVD assessment*                          |       | Staff primarily responsible for chronic ischaemic   |       |
| At enrolment into care                              | 4 (25)  | stroke management                                   |       |
| At antiretroviral therapy initiation                 | 2 (13)  | HIV physician                                       | 4 (25) |
| Yearly                                              | 9 (56)  | Non-HIV physician                                   | 10 (63) |
| At every visit                                      | 0 (0)   | Nurse                                              | 0 (0)  |
| Number of patients assessed for ASCVD risk per month|       | Nurse assistant                                     | 0 (0)  |
| 0–100                                               | 8 (50)  | Other clinical staff                                | 0 (0)  |
| 101–250                                             | 2 (13)  | Non-clinical staff                                  | 1 (6)  |
| 251–500                                             | 2 (13)  | Uncertain                                          | 0 (0)  |
| >500                                                | 1 (6)   | Training received in past 2 years for staff managing| 6 (38) |
| Uncertain                                           | 3 (19)  | chronic ischaemic stroke                            |       |
| Location of ASCVD risk assessment                   |       | Payment of chronic ischaemic stroke management costs |       |
| Within HIV clinic                                   | 13 (81) | Patient only                                        | 7 (44) |
| In same facility but not in HIV clinic              | 1 (6)   | Full public funding                                 | 4 (25) |
| Off site                                            | 0 (0)   | Co-payment (patient and public)                     | 4 (25) |
| Undefined                                           | 1 (6)   | Mixture of all                                      | 1 (6)  |
| Not available                                       | 1 (6)   |                                                   |       |
| Staff primarily responsible for ASCVD risk assessment|       |                                                   |       |
| HIV physician                                       | 13 (81) |                                                   |       |
| Non-HIV physician                                   | 0 (0)   |                                                   |       |

*a Respondents could select more than one option. ASCVD: atherosclerotic cardiovascular disease.
plasma glucose (88%), oral glucose tolerance test (81%), random plasma glucose (88%), point-of-care diabetes testing (75%), computed tomography scan (81%), brain magnetic resonance imaging (81%), computed tomography angiogram (68%), echocardiogram (88%), electrocardiogram (81%), any form of cardiac stress test (75%), 24-hour Holter monitor (69%), carotid duplex or ultrasound (69%), cardiac catheterisation (63%), cardiac troponin (75%), creatine kinase myocardial band isoenzyme (75%), creatine phosphokinase (75%) and stroke rehabilitation (75%). Cerebral thrombectomy and coronary bypass or stenting were available within the same facility as the HIV clinic at 50% of sites. Digital photography for remote diagnosis of diabetic retinopathy was available either within the HIV clinic, within the same facility as the HIV clinic or off site at 50% of sites. Blood pressure monitoring was free to patients at 69% of sites; however, most sites required patients to pay some or all the associated costs for other procedures (Table 6).

**Medication availability**

Medications available in the clinic or within the same facility to treat ASCVD-associated conditions included thiazides (88%), angiotensin-converting enzyme inhibitors (81%), calcium channel blockers (88%), beta-blockers (94%), statins (94%), fibrates (88%), ezetimibe (56%), aspirin (88%), P2Y12 inhibitors (81%), alteplase (56%) and sulphonylureas (94%). Further details on medication availability are provided in Table 7.

**Discussion**

The surveys of 16 HIV clinics in LMICs in Asia revealed several gaps in ASCVD diagnosis and management practices, in particular, a lack of ASCVD screening and management protocols. To our knowledge, this is the first study to report the capacity of HIV clinics in Asia to manage and screen for ASCVD.

### Table 6. Test and procedure availability (N=16)

| Availability and cost | Blood pressure monitor n (%) | HbA1c n (%) | Fasting plasma glucose n (%) | Oral glucose tolerance test n (%) | Random plasma glucose n (%) | Digital photography* n (%) | Point of care diabetes testing n (%) | Computed tomography scan n (%) |
|-----------------------|-----------------------------|-------------|------------------------------|----------------------------------|---------------------------|---------------------------|----------------------------------|-----------------------------|
| **Availability**       |                             |             |                              |                                  |                           |                           |                                  |                             |
| Within HIV clinic      | 15 (94)                     | 9 (56)      | 12 (75)                      | 6 (38)                           | 11 (69)                   | 1 (6)                     | 10 (63)                          | 3 (19)                       |
| In same facility but not in HIV clinic | 0 (0) | 4 (25) | 2 (13) | 7 (44) | 3 (19) | 4 (25) | 2 (13) | 10 (63) |
| Off site              | 0 (0)                       | 2 (13)      | 1 (6)                        | 1 (6)                            | 0 (0)                     | 3 (19)                    | 2 (13)                           | 2 (13)                       |
| Not available         | 1 (6)                       | 1 (6)       | 1 (6)                        | 2 (13)                           | 2 (13)                    | 8 (50)                    | 2 (13)                           | 1 (6)                        |
| Procedure or test free for patients | 11 (69) | 5 (31) | 7 (44) | 3 (19) | 5 (31) | 3 (19) | 5 (31) | 4 (25) |
| **Brain MRI**         | 3 (19)                      | 3 (19)      | 3 (19)                       | 7 (44)                           | 2 (13)                    | 2 (13)                    | 2 (13)                           | 2 (13)                       |
| **Computed tomography angiogram** | 10 (63) | 8 (50) | 11 (69) | 6 (38) | 10 (63) | 9 (56) | 9 (56) | 8 (50) |
| **Echocardiogram**    | 2 (13)                      | 4 (25)      | 1 (6)                        | 1 (6)                            | 2 (13)                    | 3 (19)                    | 3 (19)                           | 4 (25)                       |
| **ECG**               | 1 (6)                       | 1 (6)       | 1 (6)                        | 2 (13)                           | 2 (13)                    | 2 (13)                    | 2 (13)                           | 2 (13)                       |
| **Cardiac stress test** | 4 (25) | 4 (25) | 4 (25) | 5 (31) | 3 (19) | 3 (19) | 3 (19) | 2 (13) |
| **24-hour Holter monitor** | 6 (38) | 6 (38) | 6 (38) | 0 (0) | 1 (6) | 0 (0) |
| **Carotid duplex/ultrasound** | 6 (38) | 6 (38) | 6 (38) | 8 (50) | 11 (69) | 8 (50) |
| **Cardiac catheterisation** | 2 (13) | 2 (13) | 2 (13) | 4 (25) | 3 (19) | 6 (38) |
| **Cardiac troponin**  | 3 (19)                      | 3 (19)      | 3 (19)                       | 3 (19)                           | 5 (31)                    | NA                        |                                  |                             |
| **Creatine kinase MB isoenzyme** | 6 (38) | 6 (38) | 6 (38) | 0 (0) | 1 (6) | 0 (0) |
| **Creatine phosphokinase** | 6 (38) | 6 (38) | 6 (38) | 8 (50) | 11 (69) | 8 (50) |
| **Cerebral thrombectomy** | 2 (13) | 2 (13) | 2 (13) | 4 (25) | 3 (19) | 6 (38) |
| **Stroke rehabilitation** | 2 (13) | 2 (13) | 2 (13) | 4 (25) | 1 (6) | 2 (13) |
| **Coronary bypass or stenting** | 3 (19) | 3 (19) | 3 (19) | 5 (31) | NA |                   |

*For remote diagnosis of diabetic retinopathy.

*Any form of cardiac stress test. ECG: electrocardiogram; HbA1c: glycosylated haemoglobin; MB: myocardial band; MRI: magnetic resonance imaging; NA: not assessed.
For each of the major ASCVD risk factors assessed, approximately half of the surveyed sites indicated they had an assessment protocol in place. Between 56% and 75% of the sites provided some form of education to patients on these risk factors, indicating room for improvement. Education empowers patients and community members to seek care and to better manage their health [15]. In comparison with a similar survey among HIV treatment sites in Tanzania [27], education provision among our sites was higher for tobacco use (75% vs 57%), lower for alcohol use (69% vs 86%), and slightly higher for obesity and nutrition (69% vs 64%).

Routine screening for hypertension, hyperlipidaemia, diabetes and ASCVD risk was common, and sites had excellent access to blood pressure monitors, lipid and fasting plasma glucose testing, and appropriate ASCVD risk equations. However, only 64% of sites had a protocol in place for hypertension screening and fewer had protocols to screen for hyperlipidaemia, diabetes or ASCVD risk. In Asia and elsewhere, primary care systems with well-established protocols have proven to be effective in non-communicable disease prevention and management [28–30]. Protocols help to standardise medical care and optimise the utility of equipment, laboratory testing and medications. For HIV or primary care clinics, protocols can also assist in deciding appropriate patient referral for a non-communicable disease-related complication.

Many sites also lacked a protocol for the management of hypertension, hyperlipidaemia, diabetes, high ASCVD risk and chronic stroke. This finding is consistent with other studies from resource-limited countries reporting findings from HIV [27] and primary care clinics [31,32]. Importantly, the availability of medications to treat these conditions was generally good. As an example, while we found 94% of sites had statins available either within the HIV clinic or in the same facility as the HIV clinic, Leung et al. reported that less than 10% of the HIV clinics they had surveyed in Tanzania could provide simvastatin [27]. It was also encouraging to find that coronary bypass or stenting and stroke rehabilitation services were available at 88% and 94% of the surveyed sites, respectively.

Patient management of hypertension, hyperlipidaemia, diabetes and chronic stroke was usually carried out by an HIV physician. This is becoming more common in LMICs; however, in high-income countries, where integrated care has typically focused on better management of broad groups of people with multiple morbidities, HIV physicians may not have as much autonomy regarding their patient CVD care [33]. For 38% to 63% of sites, the staff member primarily responsible for patient management had received training in the last 2 years. Patients often had to pay some or all of the costs associated with diagnosis and management. Ensuring clinics are adequately staffed to address the growing ASCVD burden among PLHIV is critical. Moreover, healthcare workers must be adequately trained, encouraged to explore novel models of care and incentivised to continue developing their career track [15]. This study indicates that staff at the surveyed clinics have sufficient tools available to diagnose and manage patients appropriately.

There are several limitations to this study. First, the HIV clinics included may not be representative of HIV care across Asia, particularly in more rural areas. Second, our study is based on self-reported data collected cross-sectionally, which may be subject to recall and desirability biases. Finally, we have captured information only on the service availability and not their quality, uptake

Table 7. Medication availability (N=16)

| Characteristic       | Aspirin n (%) | P2Y12 inhibitors n (%) | Alteplase n (%) | Atorvastatin n (%) | Fluvastatin n (%) | Lovastatin n (%) | Pitavastatin n (%) | Pravastatin n (%) |
|----------------------|---------------|------------------------|-----------------|-------------------|------------------|------------------|-------------------|------------------|
| Availability         |               |                        |                 |                   |                  |                  |                   |                  |
| Within HIV clinic    | 3 (19)        | 6 (38)                 | 0 (0)           | 9 (56)            | 3 (19)           | 2 (13)           | 6 (38)            | 4 (25)           |
| In same facility but not in HIV clinic | 11 (69) | 7 (44) | 9 (56) | 5 (31) | 3 (19) | 5 (31) | 5 (31) | 6 (38) |
| Off site             | 1 (6)         | 2 (13)                 | 4 (25)          | 1 (6)             | 3 (19)           | 3 (19)           | 1 (6)             | 3 (19)           |
| Not available        | 1 (6)         | 1 (6)                  | 3 (19)          | 1 (6)             | 7 (44)           | 6 (38)           | 4 (25)            | 3 (19)           |
| Rosuvastatin         | 8 (50)        | 7 (44)                 | 7 (44)          | 9 (56)            | 2 (13)           | 5 (31)           | 10 (63)           | 9 (56)           |
| Simvastatin          | 5 (31)        | 6 (38)                 | 5 (31)          | 5 (31)            | 4 (25)           | 4 (25)           | 4 (25)            | 4 (25)           |
| Gemfibrozil          | 1 (6)         | 2 (13)                 | 1 (6)           | 2 (13)            | 4 (25)           | 0 (0)            | 1 (6)             | 6 (38)           |
| Fenofibrate          | 2 (13)        | 1 (6)                  | 2 (13)          | 1 (6)             | 7 (44)           | 3 (19)           | 2 (13)            | 2 (13)           |
| Clofibrate           |               |                        |                 |                   |                  |                  |                   |                  |
| Ezetimibe            |               |                        |                 |                   |                  |                  |                   |                  |
| Thiazides            |               |                        |                 |                   |                  |                  |                   |                  |
| ACE-inhibitors       |               |                        |                 |                   |                  |                  |                   |                  |
| CCBs                 |               |                        |                 |                   |                  |                  |                   |                  |
| Beta-blockers        | 10 (63)       | 4 (25)                 | 8 (50)          | 3 (19)            | 4 (25)           | 6 (38)           | 5 (31)            | 2 (13)           |
| Sulphonylureas       | 4 (25)        | 11 (69)                | 7 (44)          | 8 (50)            | 7 (44)           | 6 (38)           | 7 (44)            | 6 (38)           |
| Meglitinides         | 0 (0)         | 1 (6)                  | 1 (6)           | 2 (13)            | 3 (19)           | 3 (19)           | 2 (13)            | 3 (19)           |
| AGIs                 | 2 (13)        | 0 (0)                  | 0 (0)           | 3 (19)            | 2 (13)           | 1 (6)            | 2 (13)            | 5 (31%)          |
| DPP-4 inhibitors     |               |                        |                 |                   |                  |                  |                   |                  |
| Incretin mimetics    |               |                        |                 |                   |                  |                  |                   |                  |

ACE: angiotensin-converting enzyme; AGIs: alpha-glucosidase inhibitors; CCBs: calcium channel blockers; DPP: dipeptidyl peptidase.
or coverage. Further studies examining the quality of ASCVD care provided in Asian HIV clinics and impact of ASCVD prevention and care initiatives among PLHIV are warranted.

This study shows ASCVD care is generally well integrated among urban HIV centres in LMICs in Asia. The consistent availability of clinical screening, diagnostic testing and procedures, and ASCVD medication is a strength in the current system that should be leveraged to improve implementation of cardiovascular care protocols.

Acknowledgements
The authors would like to acknowledge all site staff involved in completing the study surveys.

Conflicts of interest
DCB has received research funding from Gilead Sciences and is supported by a National Health and Medical Research Council Early Career Fellowship (APP1140503); MGL has received unrestricted grants from Boehringer Ingelheim, Gilead Sciences, Merck Sharp & Dohme, Bristol-Myers Squibb, Janssen-Cilag and Viiv HealthCare, consultancy fees from Gilead Sciences, and data and safety monitoring board sitting fees from Sirtex Pty Ltd; AHS has received research funding and travel support from Viiv Healthcare; OTN is supported by a National Medical Research Council Clinician Scientist Award (MOH-000276). All other authors report no potential conflicts of interest.

Funding
The International Epidemiology Database to Evaluate AIDS (ieDeA) is supported by the National Institute of Allergy and Infectious Diseases (100000060), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (100009633), the National Institute on Drug Abuse (100000026), the National Institute of Mental Health (100000025) in accordance with the regulatory requirements of the National Institutes of Health under award numbers U01AI069911 (East Africa), U01AI069919 (West Africa), U01AI096299 (Central Africa), U01AI069924 (Southern Africa) and U01AI069907 (Asia-Pacific). The Kirby Institute (data centre for the ieDeA Asia-Pacific) is funded by the Australian Government Department of Health and Ageing (50110001027) and is affiliated with the Faculty of Medicine, University of New South Wales (Sydney, Australia). This work is solely the responsibility of the authors and does not necessarily represent the official views of any of the institutions mentioned.

References
1. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50 (10): 1387–1396.
2. Lewden C, May T, Rosenthal E et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the ‘Mortalité 2000 and 2005’ surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008; 48 (5): 590–598.
3. Pellaè FJ, Jr, Baker RK, Moorman AC et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43 (1): 27–34.
4. Allen L. Are we facing a noncommunicable disease pandemic? J Epidemiol Glob Health 2017; 7 (1): 5–9.
5. Currier JS, Taylor A, Boyd F et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33 (4): 506–512.
6. Freiberg MS, Chang CC, Kuller LH et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173 (8): 614–622.
7. Tenart VA, Lee H, Hadgkin C et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92 (7): 2506–2512.
8. Freiberg MS, So-Armah K. HIV and cardiovascular disease: we need a mechanism, and we need a plan. J Am Heart Assoc 2016; 4 (3): e003411.
9. Eyawo O, Franco-Villalobos C, Hull MW et al. Changes in mortality rates and causes of death in a population-based cohort of persons living with and without HIV from 1996 to 2012. BMC Infect Dis 2013; 17 (1): 114.
10. Smith CJ, Ryom L, Weber R et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (10-A-D): a multicohort collaboration. Lancet 2014; 384 (9939): 241–248.
11. Bijker R, Jamsakul A, Uy E et al. Cardiovascular disease-related mortality and factors associated with cardiovascular events in the TREAT Asia HIV Observational Database (TAHOD). HIV Med 2018; 20 (3): 183–191.
12. Maher D, Ford N. Action on noncommunicable diseases: balancing priorities for prevention and care. Bull World Health Organ 2011; 89 (7): 547–547A.
13. Janssens B, Van Damme W, Raleigh B et al. Offering integrated care for HIV/AIDS, diabetes, and hypertension: the experience of 13 HIV cohort studies. J Acquir Immune Defic Syndr 2007; 51 (3): 174–178.
14. Duffy M, Ojikutu B, Andrian S et al. Non-communicable diseases and HIV care and treatment: models of integrated service delivery. Trop Med Int Health 2017; 22 (8): 926–937.
15. WHO. Action plan for the prevention and control of noncommunicable diseases in South-East Asia, 2013–2020. Available at: www.who.int/nmh/ncc-tools/who-regions-south-east-asia/en/ (accessed January 2020).
16. UNAIDS. Fact Sheet – World AIDS Day 2019. Available at: www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf (accessed January 2020).
17. Egger M, Ekkouvi DK, Williams C et al. Cohort profile: the International Epidemiological Databases to Evaluate AIDS (ieDEA) in sub-Saharan Africa. Int J Epidemiol 2012; 41 (5): 1256–1264.
18. Gange SJ, Kitahata MM, Saag MS et al. Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). Int J Epidemiol 2007; 36 (2): 294–301.
19. McGowan CC, Cahn P, Gatuuzzo E et al. Cohort profile: Caribean, Central and South America Network of HIV cohorts working for HIV research (CCASNet) collaboration with the International Epidemiologic Databases to Evaluate AIDS (ieDEA) programme. Int J Epidemiol 2007; 36 (5): 965–976.
20. Zhou J, Kumarasamy N, Ditangco R et al. The TREAT Asia HIV Observational Database: baseline and retrospective data. J Acquir Immune Defic Syndr 2005; 38 (2): 174–179.
21. The World Bank. World Bank Country and Lending Groups – Country Classification. Available at: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519 (accessed January 2020).
22. Mugglin C, Egger M, Urasa M et al. HIV care and treatment sites’ capacity to manage NCDs: diabetes and hypertension. 21st International Workshop on HIV and Hepatitis Observational Databases, 2017, Lisbon, Portugal. Abstract 108.
23. Parcesepe A, Mugglin C, Egger M et al. Capacity to screen and manage mental health disorders at HIV treatment sites in low- and middle-income countries. 9th IAS Conference on HIV Science, 2017 Paris, France. Abstract 2984.
24. Mugglin C, Mulenga L, Mweamba A et al. Site capacity to screen for and manage renal dysfunction among HIV-infected persons receiving care in low- and middle-income countries 9th IAS Conference on HIV Science, 2017 Paris, France. Abstract 2944.
25. Harris PA, Taylor R, Thielke R et al. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42 (2): 377–381.
26. Maheshwari A, Norby FL, Roetker NS et al. Refining prediction of atrial fibrillation-related stroke using the P1-CHADS2-VAsc score. Circulation 2019; 139 (2): 180–191.
27. Leung C, Aris E, Mhlu A et al. Preparedness of HIV care and treatment clinics for the management of coexistent non-communicable diseases: a cross-sectional survey. BMC Public Health 2016; 16 (1): 1002.
28. Farzadfar F, Murray CJ, Gakidou E et al. Effectiveness of diabetes and hypertension management by rural primary health-care workers (Behwarkar workers) in Iran: a nationally representative observational study. Lancet 2012; 379 (9810): 47–54.
29. Liang X, Chen J, Liu Y et al. The effect of hypertension and diabetes management in Southwest China: a before- and after-intervention study. PLoS ONE 2014; 9 (3): e91801.
30. Rakpin M, Melaku Z, Bruce K et al. Strengthening health systems for chronic care: leveraging HIV programs to support diabetes services in Ethiopia and Swaziland. J Trop Med 2012; 2012: 137460.
31. Parkhe A, Kumar S, Goyal V et al. Assessment of primary care facilities for cardiovascular disease preparedness in Madhya Pradesh, India. BMC Health Serv Res 2015; 15: 408.
32. Van Minh H, Do YK, Bautista MA et al. Describing the primary care system capacity for the prevention and management of non-communicable diseases in rural Vietnam. Int J Health Plann Manage 2014; 29 (2): e159–e173.
33. Moumier-Jack S, Mayhew SH, Mays N. Integrated care: learning between high-income, and low- and middle-income country health systems. Health Policy Plan 2017; 32 (Suppl 4): i6–i12.

ORIGINAL RESEARCH
Journal of Virus Eradication 2020; 6: 11–18